Repare Therapeutics RPTX

$ 2.87 1.06%

Quarterly report 2024-Q3
added 11-07-2024

Repare Therapeutics Balance Sheet 2011-2024 | RPTX

Annual Balance Sheet Repare Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-108 M	-154 M	-327 M	-322 M	-93.7 M	-10.7 M	-	-	-	-	-	-	-
Long Term Debt	1.01 M	3.26 M	5.59 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.4 M	2.17 M	1.72 M	697 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	59.2 M	145 M	34.4 M	-	-	-	-	-	-	-
Total Current Liabilities	39.1 M	78.6 M	35.1 M	11 M	-	-	-	-	-	-	-	-	-
Total Liabilities	41.8 M	84.6 M	80.3 M	70.3 M	149 M	36.3 M	-	-	-	-	-	-	-
Deferred Revenue	10.2 M	53.1 M	11.9 M	2.07 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-333 M	-239 M	-210 M	-103 M	-49.9 M	-22.7 M	-	-	-	-	-	-	-
Total Assets	254 M	364 M	369 M	357 M	103 M	13.9 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	111 M	160 M	334 M	326 M	95 M	-	-	-	-	-	-	-	-
Book Value	212 M	280 M	288 M	287 M	-46.1 M	-22.4 M	-	-	-	-	-	-	-
Total Shareholders Equity	212 M	280 M	288 M	287 M	-46.1 M	-22.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Repare Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	346 K	218 K	561 K	1.01 M	1.59 M	2.23 M	2.78 M	3.26 M	3.77 M	-	5.15 M	5.59 M	5.62 M	3.54 M	3.24 M	3.31 M	3.31 M	3.31 M	3.31 M	439 K	439 K	439 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	31.4 M	31.7 M	31.1 M	41.8 M	53 M	56.2 M	85.1 M	84.6 M	103 M	-	78.5 M	80.3 M	77.4 M	75.6 M	71.4 M	70.3 M	70.3 M	70.3 M	70.3 M	12.8 M	12.8 M	12.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	1.07 M	10.2 M	20.5 M	24.4 M	52.8 M	53.1 M	34.8 M	-	11.9 M	11.9 M	8.92 M	8.76 M	2.08 M	2.07 M	2.07 M	2.07 M	2.07 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-389 M	-355 M	-320 M	-333 M	-305 M	-286 M	-274 M	-239 M	-208 M	-	-245 M	-210 M	-182 M	-151 M	-125 M	-103 M	-103 M	-103 M	-103 M	-49.9 M	-49.9 M	-49.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	206 M	235 M	263 M	254 M	286 M	302 M	336 M	364 M	409 M	-	337 M	369 M	296 M	321 M	339 M	357 M	357 M	357 M	357 M	103 M	103 M	103 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	80.5 M	79.8 M	103 M	111 M	107 M	116 M	121 M	160 M	155 M	-	305 M	334 M	261 M	294 M	311 M	326 M	326 M	326 M	326 M	94.8 M	105 M	94.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	175 M	204 M	232 M	212 M	233 M	245 M	251 M	280 M	306 M	-	259 M	288 M	218 M	245 M	268 M	287 M	287 M	287 M	287 M	89.9 M	89.9 M	89.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	175 M	204 M	232 M	212 M	233 M	245 M	251 M	280 M	306 M	226 M	259 M	288 M	218 M	245 M	268 M	287 M	287 M	287 M	287 M	-46.1 M	-46.1 M	-46.1 M	-27.2 M	-22.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency